By Josh Beckerman
Myriad Genetics shares were down 6.5% to $12.88 after hours as the company reported earnings and said Chief Executive Paul J. Diaz will leave the company April 30.
The genetic testing and precision medicine company said Monday fourth-quarter revenue rose 7% to $210.6 million. Adjusted net income declined to $3.2 million from $3.5 million. Myriad reaffirmed 2025 guidance.
Myriad said Chief Operating Officer Sam Raha will become CEO. Mark S. Verratti, Myriad's chief commercial officer, will be COO. Diaz, who joined Myriad in 2020, is returning to private equity firm Cressey & Co.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 24, 2025 17:49 ET (22:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.